Arrowhead shares sink with news of Novartis RNAi closure; Nordic Capital leads bidders for nicotine patch maker;

> Shares of Arrowhead ($ARWR) dropped over 8% with news that Novartis would be closing a large portion of its RNAi research arm in Boston, according to Street Register. Brief

> Swedish Nordic Capital is said to be a leading bidder for LTS Lohmann Therapie-Systeme, a German nicotine patch maker, according to a report in Bloomberg BusinessWeek. Story

> Moberg Pharma inked a deal with Oracain II Aps for global rights to its oral formulation of bupivacaine to treat pain in the oral cavity. Release

> IntelGenx ($IGXT) snagged a patent for its AdVersa mucoadhesive drug delivery technology. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.